„Donanemab“: Novel Drug Slows Cognitive Decline in Alzheimer’s Disease

In a clinical trial, a novel drug called „Donanemab” has led to a slowing of cognitive decline in people with early Alzheimer's disease. This was announced by the manufacturer Eli Lilly, which is seeking approval for the drug in the United States and other countries.

„Donanemab“ is a so-called amyloid antibody and targets specific proteins that are deposited in the brain in the course of Alzheimer’s disease. A similar drug called „Lecanemab” is currently undergoing the regulatory process in the EU. In the US, „Lecanemab“ is already on the market. While conventional drugs only have a symptomatic effect without addressing the causes of Alzheimer's, the novel drugs address the roots of the disease.

Three DZNE experts – Christian Haass, Frank Jessen and Stefan Teipel – have commented on this development for the Science Media Center (German).

May 2023

Welcome to our website, here you can inform yourself basically cookie-free.

We would be pleased if you would allow a cookie to be set for analysis purposes in order to optimise our provided information. All data are pseudonymous and are only used by the DZNE. We deliberately avoid third-party cookies. You can deselect this setting at any time here.

Your browser allows the setting of cookies: